Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity

International Journal of Cancer

Volumn 121, Issue 5, 2007, Pages 955-965

  Asanuma, Kunihiro ^a   Yoshikawa, Tomoaki ^a   Hayashi, Tatsuya ^a   Akita, Nobuyuki ^a   Nakagawa, Norimi ^a   Hamada, Yasuhiko ^a   Nishioka, Junji ^a   Kamada, Haruhiko ^a   Gabazza, Esteban C ^a   Ido, Masaru ^a   Uchida, Atsumasa ^a   Suzuki, Koji ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Invasion; Metastasis; Protein C inhibitor; Serine protease inhibitor

Indexed keywords

ANTITHROMBIN; MATRIGEL; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEINASE INHIBITOR; UROKINASE;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL INVASION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN C INHIBITOR; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34250752553     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22773     Document Type: Article

References (40)

1. Marlar RA, Griffin JH. Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest 1980;66:1186-9.
2. Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983;258:163-8.
3. Suzuki K, Nishioka J, Kusumoto H, Hashimoto S. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem (Tokyo) 1984;85:187-95.
4. Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995;270:25336-9.
5. Meijers JCM, Kanters DH, Vlooswijk RA, van Erp HE, Hessing M, Bouma BN. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988;27:4231-7.
6. Stief TW, Radtke KP, Heimburger N. Inhibition of urokinase by protein C-inhibitor (PCI). Evidence for identity of PCI and plasminogen activator inhibitor 3. Biol Chem Hoppe Seyler 1987;368:1427-33.
7. Francis RB, Thomas W. Behavior of protein C inhibitor in intravascular coagulation and liver disease. Thromb Haemost 1984;52:71-4.
8. Radtke KP, Fernandez JA, GreenGard JS, Tang WW, Wilson CB, Loskutoff DJ, Scharrer I, Griffin JH. Protein C inhibitor is expressed in tubular cells of human kidney. J Clin Invest 1994;94:2117-24.
9. Laurell M, Christensson A, Abrahamsson PA, Stenflo J, Lilja H. Protein C inhibitor in body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J Clin Invest 1992;89:1094-101.
10. Wakita T, Hayashi T, Yuasa H, Nishioka J, Kawamura J, Suzuki K. Molecular cloning, tissue distribution and androgen regulation of rat protein C inhibitor. FEBS Lett 1998;429:146-54.
11. Zechmeister-Machhart M, Uhrin P, Hufnagl P, Geiger M, Binder BR. Molecular cloning, and tissue distribution of mouse protein C inhibitor (PCI). Immunophamacol 1996;32:96-8.
12. Hayashi T, Nishioka J, Kamada H, Asanuma K, Kondo H, Gabazza EC, Ido M, Suzuki K. Characterization of a novel human protein C inhibitor (PCI) gene transgenic mouse useful for studing the role of PCI in physiological and pathological conditions. J Thromb Haemost 2004;2:949-61.
13. Uhrin P, Dewerchin M, Hilpert M, Chrenek P, Schofer C, Zechmeister-Machhart M, Kronke G, Vales A, Carmeliet P, Binder BR, Geiger M. Disruption of the protein C inhibitor gene results in impaired spermatogenesis and male infertility. J Clin Invest 2000;106:1531-9.
14. Stump DC, Thienpoint M, Collen D. Purification and characterization of a novel inhibitor of urokinase from human urine. J Biol Chem 1986;261:12759-66.
15. Palmieri D, Lee JW, Juliano RL, Church FC. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem 2002;43:40950-7.
16. Wakita T, Hayashi T, Nishioka J, Tamaru H, Akita N, Asanuma K, Kamada H, Gabazza EC, Ido M, Kawamura J, Suzuki K. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma. Int. J Cancer 2004;108:516-23.
17. Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akira M, Yamamoto S, Hashimoto S. Characterization of a cDNA for human protein C inhibitor. A new member of the serine protease inhibitor superfamily. J Biol Chem 1987;262:611-16.
18. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-91.
19. Hayashi T, Suzuki K. Gene organization of human protein C inhibitor, a member of SERPIN family proteins encoded in five exons. Int J Hematol 1993;58:213-24.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1982;162:156-9.
21. Fujita M, Izutani W, Takahashi K, Nishizawa K, Shinoro H, Koga J. Role of each Asn-linked glycan in the anticoagulant activity of human protein C inhibitor. Thromb Res 2002;105:95-102.
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage. Nature 1970;227:680-5.
23. Hayashi T, Nishioka J, Shigekiyo T, Saito S, Suzuki K. Protein S Tokushima: abnormal molecule with substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood 1994;83:683-90.
24. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
25. McMahon GA, Petitclerc E. Stefansson S, Smith E, Wong MKK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001;276:33964-8.
26. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-28.
27. Seo K, Choi J, Park M, Rhee C. Angiogenesis effects of nerve growth factor (NGF) on rat corneas. J Vet Sci 2001;2:125-30.
28. Schnaper HW, Barnathan ES, Mazar A, Maheshwari S, Ellis S, Cortez SL, Baricos WH, Kleinman HK. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995;65:107-18.
29. Jordan RE, Nelson RM, Kilpatrick J, Newgren JO, Esmon PC, Fournel MA. Inactivation of human antithrombin by neutrophil elastase. J Biol Chem 1989;264:10493-500.
30. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992;313:355-64.
31. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002;100:3245-52.
32. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8.
33. Zhang W, Chuang YJ, Swanson R, Li J, Seo K, Leung L, Lau LF, Olson ST. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004;103:1185-91.
34. Uchiba M, Okajima K, Oike Y, Ito Y, Fukudome K, Isobe H, Suda T. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res 2004;95:34-41.
35. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001;276:8135-41.
36. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003;8:72-9.
37. Zhang W, Swanson R, Izaguirre G, Xiong Y, Lau LF, Olson ST. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 2005;106:1621-8.
38. Miao RQ, Chen V, Chao L, Chao J. Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol 2003;284:C1604-C1613.
39. Neese LL, Wolfe CA, Church FC. Contribution of basic residues of the D and H helices in heparin binding to protein C inhibitor. Arch BiochemBiophys 1998;355:101-8.
40. Shirk RA, Elisen MG, Meijers JC, Church FC. Role of the H helix in heparin binding to protein C inhibitor. J Biol Chem 1994;269:28690-5.